Oak NAD+ Review: An Anti-Ageing Line With No Published Price

Almost everything written about Oak, including in our own records until this week, says it is a GLP-1 company. It is not, or not only. Oak runs six active programmes, and one of them — the Anti-Aging programme — names NAD+, glutathione, MIC+B12 injections and metformin in Oak's own patient consent text. A separate programme covers sermorelin and tesamorelin. A third, the skincare line, includes a topical NAD+.

None of that is on a product page you can browse. It is in Oak's own checkout configuration, which the site serves unauthenticated to anyone who asks for it. That is how we know the programme exists.

It is also how we know something else: every one of those six programmes returns a price of zero.

The price does not exist until you have been approved

Oak's checkout configuration prices the GLP-1 line and returns `0.00` for everything else. Ask its system for the drug detail behind any programme and it answers with an empty response. Ask for a checkout and it refuses without a session. There is no NAD+ price, no glutathione price, no MIC+B12 price and no sermorelin price anywhere on the public site or behind it.

What that means practically is that the figure is set after you have completed the quiz and a clinician has approved you — after you have handed over your health history, and after there is a prescription in play. We have no number to publish, so we publish none. We are not going to estimate one from the GLP-1 line either: a price nobody can navigate to is not a price, and a price we compute for a company is a fabrication once it is printed.

That is why Oak sits last among the companies we are paid by. It is below even the three that gate a headline behind an intake, because those three at least publish an entry figure you can read before handing over an email address. Oak publishes nothing. Not a floor, not a range, not a "starting at".

Omitting it from the board entirely would tell a reader nothing. Ranking it last and saying exactly what is missing tells them something.

The one part of the site that is priced, and what it shows

The weight-loss line is the only priced thing Oak publishes, and it is the only evidence available about how this company handles a number. There are five mutually inconsistent figures across one site:

• •$119 semaglutide / $185 tirzepatide — the homepage hero and the product cards, under the line "One price · All dosages · No subscriptions"
• •$133 / $199 — the page's own meta description, and its og: and twitter: descriptions
• •$167/mo — the homepage "How Oak Compares" table, and `/product`
• •$190/mo — the same comparison table on `/weightloss` and `/weight-loss`
• •$119/month — the homepage FAQ

We anchor on the hero's $119 and $185 because they are what a visitor actually sees, and we report the spread because the spread is the finding. A company that publishes five prices for one product on one site is a company whose unpublished prices are worth being cautious about — which is the only inference this section is making.

An unpriced "$200 off new patient offer" and a "Save up to 60% vs retail" banner run alongside, with no published mechanics for either.

"No subscriptions", four times, beside a subscription

Oak's hero says "No subscriptions" four separate times. Its terms of use say: *"Your Subscription fee may change from time to time… you can cancel… your subscription."*

Both are Oak's own words on Oak's own site. We are not going to guess which one describes what your card will be charged; we are pointing out that the marketing and the contract disagree about the most basic property of the purchase.

The state list points at a page that does not exist

This is the clearest single failure on the site, and it is checkable in about a minute.

Oak's `/terms-of-use` page carries two separate, separately dated terms documents. The first says Oak *"is providing the Services of our Site to 45 states"*. The second says eligibility depends on a "States Where We Currently Operate" list "found in our FAQ".

There is no FAQ. `/faq`, `/faqs`, `/help`, `/frequently-asked-questions` and `/states` all return 404, and no FAQ URL appears in the sitemap. The state list is a circular reference to a missing page, so the question "can Oak ship to me" has no published answer at all — only a number in one document that the other document supersedes with a pointer to nothing.

Six legal entities, one storefront

The `/terms-of-use` page alone names four different companies: Oak Longevity Holdings Corp, Oak Longevity Corp, Leaf Longevity Holdings Corp DBA Oak Longevity, and Oaklovesyou LLC — the last inside a second terms document appended below the first with its own separate date.

The homepage footer adds two more: Flow Longevity Holdings Corp and Mito Health Holdings Corp. Six corporate names across one website.

For a reader that matters in one specific way: it is not obvious which entity you are contracting with, and that is the entity you would have to deal with if something went wrong.

Nobody is named

No compounding pharmacy is named. No clinician is named. No medical director, no NPI, no bio page. The prescribing network is Beluga Health, and we know that only because it appears inside the consent JSON — it is not stated on any page a visitor would read.

Compare that with what the better-disclosed companies on our board do. Pallas Health names six pharmacies and two physicians whose NPIs verify in the federal registry. Breeze Meds names four pharmacies with phone numbers. Oak names nobody, which means there is nothing about its supply chain a reader can check independently.

There is also no LegitScript seal ID. Oak's footer links to LegitScript's keyword checker and renders a locally hosted graphic; there is no seal identifier anywhere in the markup, so the certification cannot be resolved against LegitScript's own records at all. A checker link proves nothing — anyone can link one — so we do not repeat any certification claim for this company.

What is clean: Oak's own enforcement record. We screened the FDA warning-letter index for "oaklovesyou", "oak longevity", "Oak Longevity Holdings", "Beluga Health" and "Quello", and every query returned zero, with a known positive control returning in the same pass so the result is a real clean rather than a broken search.

The Women's Health tile leads into the NAD+ intake

Worth knowing if you land on the homepage: Oak ships a live Women's Health tile while `/weight-loss` and `/start` both label Men's and Women's Health "Coming Soon". The tile is wired to the Anti-Aging programme — the NAD+, glutathione and MIC+B12 intake — because there is no women's-health questionnaire in the catalogue at all.

So a woman clicking "Women's Health" begins an NAD+ and glutathione intake. That is not a hidden defect; it is visible from the link target. But it is not what the tile says it is.

What Oak does not sell, whatever its config contains

Two supplement products — a Gut Health Vitamin Pack and a Longevity Vitamin Pack, both at $165 — exist in Oak's product system and are both flagged inactive, with no over-the-counter products attached. They are built and switched off. They are not purchasable, and nobody should list them as products Oak sells.

Refunds: a hard no

Oak's terms are unusually blunt, and we quote them because vagueness here is the more common problem: "Once a provider has approved and prescribed your treatment and your order has been sent to our pharmacy… that order can no longer be cancelled and is non-refundable… even if you attempt to stop, hold, reroute, return, or cancel the shipment directly with FedEx." Disputes go to binding AAA arbitration and class actions are waived.

Read that next to the pricing situation and the shape of the decision becomes clear: the price is disclosed to you at the moment the purchase becomes non-refundable.

One last inconsistency, small but of a piece with the rest: Oak's `/product` page says "Trusted by 50,000+" while its homepage says "10,000+ Satisfied Patients" in one place and "Trusted by 5,000+ members" in another.

The evidence, which is the same for every company we rank

No rigorous human trial shows that injected or topical NAD+ improves cognition, focus or energy. That position does not change for a paid partner, and it does not change for our own top pick either. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ levels and did not improve cognition versus placebo¹; a second randomised trial in subjective cognitive decline and mild cognitive impairment found no cognitive benefit²; and the only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome at all³.

Our full position is in the review of what the NAD+ cognition evidence supports, and the compounded preparations dispensed here are not FDA-approved products — a compounded drug is not a generic equivalent of an approved one⁴.

If the reason you are here is that your thinking feels slow, the practical routes out of brain fog are a better place to start than an intake whose price you will not see until you have been approved.

The bottom line

Oak really does sell NAD+, and it sells it alongside glutathione, MIC+B12 and metformin in a named anti-ageing programme with sermorelin and tesamorelin beside it. The stored industry record that Oak is a GLP-1-only company is wrong, and we have corrected it.

What we cannot tell you is what any of it costs, because Oak does not publish a figure for a single non-GLP-1 product — not a floor, not a range. It names no pharmacy, no clinician and no medical director. It has no LegitScript seal ID to check. Its terms are two documents naming four companies, one of which points its state list at an FAQ that does not exist. Its hero says "No subscriptions" four times while its terms describe a subscription. And the one part of the site that is priced carries five different prices for the same product.

Its enforcement record is clean, its clinician review is real, and the anti-ageing programme is genuine. Everything else about the purchase is something you find out after you have been approved.